BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/25/2024 8:28:59 AM | Browse: 337 | Download: 1113
 |
Received |
|
2023-11-06 09:24 |
|
Peer-Review Started |
|
2023-11-06 09:24 |
|
First Decision by Editorial Office Director |
|
2023-11-16 02:12 |
|
Return for Revision |
|
2023-11-16 02:12 |
|
Revised |
|
2023-11-22 00:32 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-01-12 02:42 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-01-12 07:45 |
|
Articles in Press |
|
2024-01-12 07:45 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-01-18 05:13 |
|
Publish the Manuscript Online |
|
2024-01-25 08:28 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jing-Hao Zhou, Qi-Jun Yi, Ming-Yan Li, Yan Xu, Qi Dong, Cong-Ying Wang and Hai-Yan Liu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Science and Technology Innovation Development Project of Tai’an |
2021NS160 |
| the Medical and Health Science and Technology Development Plan of Shandong Province |
202102010647 |
|
| Corresponding Author |
Hai-Yan Liu, MD, Doctor, Doctor, Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University, No. 706 Taishan Street, Tai’an 271000, Shandong Province, China. fylhy1998@163.com |
| Key Words |
Inetetamab; Gastric cancer; Human epidermal growth factor receptor-2 protein; Tegafur; Case report |
| Core Tip |
In this paper, we present a case involving a patient with human epidermal growth factor receptor-2 (HER2)-positive gastric cancer who was received oxaliplatin combined with tegafur as the first-line treatment post surgery. The patient was diagnosed with postoperative recurrence of gastric adenocarcinoma. He received inetetamab, an innovative domestically developed anti-HER2 monoclonal antibody, combined with tegafur chemotherapy as the second-line treatment. Evaluation of the efficacy of the second-line treatment revealed that the patient achieved a stable condition. This is significant because We provided a practical reference case for HER2-positive gastric cancer patients who was received inetetamab that is an innovative domestically developed anti-HER2 monoclonal antibody, which may help to provide survival benefits to some extent. |
| Publish Date |
2024-01-25 08:28 |
| Citation |
Zhou JH, Yi QJ, Li MY, Xu Y, Dong Q, Wang CY, Liu HY. Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report. World J Clin Cases 2024; 12(4): 820-827 |
| URL |
https://www.wjgnet.com/2307-8960/full/v12/i4/820.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v12.i4.820 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
